Predicting toxicity after androgen deprivation:  skeletal adverse events Fred Saad MD FRCS
BMD changes after orchidectomy 0 0.2 0.4 0.6 0.8 1 1.2 1.4 2 4 6 8 10 12 14 Time After Orchidectomy (yr) BMD (g/cm  2  ) S...
ADT and Fractures  Shahinian VB, et al.  N Engl J Med.  2005;352:154-164. Years After Diagnosis Unadjusted Fracture-Free  ...
FRAX
Treatment options
Predicting bone metastases
Rising PSA in Non-Metastatic CRPC: PSA Levels Smith MR, et al.  J Clin Oncol  2005;23:2918-2925. 0.5 1 1.5 2.0 2.5 3.0 Pro...
Rising PSA in Non-Metastatic CRPC:  PSA Doubling Time (PSADT) Smith MR, et al.  J Clin Oncol  2005;23:2918-2925 . 0.5 1 1....
# Bone Lesions and Risk for SRE > 3 Bone Lesions Versus ≤ 3 Bone Lesions Shirina N, et al. Presented at ASCO 2006. Poster ...
<ul><li>3 Bone Lesions Associated  With Shorter Time to SRE </li></ul>Baseline (n = 376) P  < .0001 < 3 0.0 0.1 0.2 0.3 0....
<ul><li>3 Bone Lesions  Associated With Shorter Survival </li></ul>Baseline (n = 376) P  < .0001 0 3 6 9 12 15 18 21 24 Ti...
Bone Markers
Prognostic Implications of Bone Markers: Relative Risks in Prostate Cancer P  value <0.001 <0.001 <0.001 <0.001 <0.001 <0....
Normalization of NTX Levels vs Clinical Outcomes Among Patients With High NTX at Baseline 0 0.5 1.0 1.5 2.0 First SRE 0.61...
NTX Normalization Correlated With Improved Survival Versus Persistently Elevated NTX  Proportion deceased,  % patients Tim...
Survival Benefit by  Percentage Reduction From Baseline NTX High NTX, NTX >64 nmol/mmol creatinine Relative Risk of Death ...
Survival by Percentage Change From Baseline NTX in Placebo Group  *Calculated as ([Baseline NTX minus 3-month NTX] / basel...
Treatment options
Upcoming SlideShare
Loading in …5
×

F. Saad - Highlights of Day 2 breakout sessions (Oncology room)

414 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
414
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • 07/08/11 07:58
  • Elevation in serum PSA levels after surgery or radiation predates clinically or radiographically detectable metastatic disease. In a recent study, Smith et al. confirmed that baseline PSA predicts time to first bone metastasis and overall survival in patients with non-metastatic prostate cancer. 1 Different tertiles of PSA (&lt;7.7, 7.7 to 24, and &gt;24 ng/mL), as shown on the graph, were associated with different bone metastasis-free survival ( P &lt;0.001). Also, baseline PSA levels &gt; 10 ng/mL (RR,3.18;95% CI, 2.30 - 8.21; P &lt; 0.001) predicted shorter time to first bone metastasis. Reference: 1. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-2925.
  • Rapid PSA doubling time (PSADT) predicts shorter time to first bone metastasis and shorter survival. 1 Different tertiles of PSADT, shown on graph, were associated with different bone metastasis-free survival. The independent predictive value of PSA velocity suggests that PSA kinetics may provide an effective strategy to identify men at high risk for bone metastases or death. As the optimal management of patients at high risk of metastatic disease remains uncertain, frequency of bone scans should be based on overall risk factors. Reference: 1. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-2925.
  • Zoledronic Acid (ZOMETA ® ) in Breast Cancer
  • Zoledronic Acid (ZOMETA ® ) in Breast Cancer
  • Zoledronic Acid (ZOMETA ® ) in Breast Cancer
  • 07/08/11 07:58 Zoledronic Acid (ZOMETA ® ) in Breast Cancer
  • 07/08/11 07:58
  • 07/08/11 07:58
  • 07/08/11 07:58
  • 07/08/11 07:58
  • F. Saad - Highlights of Day 2 breakout sessions (Oncology room)

    1. 1. Predicting toxicity after androgen deprivation: skeletal adverse events Fred Saad MD FRCS
    2. 2. BMD changes after orchidectomy 0 0.2 0.4 0.6 0.8 1 1.2 1.4 2 4 6 8 10 12 14 Time After Orchidectomy (yr) BMD (g/cm 2 ) Stepan et al. JCEM 1989;69:523 Normal Range early “rapid” bone loss 4-8% per yr
    3. 3. ADT and Fractures Shahinian VB, et al. N Engl J Med. 2005;352:154-164. Years After Diagnosis Unadjusted Fracture-Free Survival (%) <ul><li>Over a 4-year period </li></ul><ul><li>19.4% fractures on ADT </li></ul><ul><li>12.6% fractures not on ADT </li></ul>2 3 4 5 6 7 8 9 10 1 0 100 90 80 70 60 50 40 30 20 10 No ADT (N=32,931) GnRH Agonist, 1- 4 doses (N = 3763) GnRH Agonist, 5 - 8 doses (N = 2171) GnRH Agonist,  9 doses (N = 5061) Orchiectomy (N = 3399)
    4. 4. FRAX
    5. 5. Treatment options
    6. 6. Predicting bone metastases
    7. 7. Rising PSA in Non-Metastatic CRPC: PSA Levels Smith MR, et al. J Clin Oncol 2005;23:2918-2925. 0.5 1 1.5 2.0 2.5 3.0 Proportion of patients with bone metastases or death Years since random assignment PSA >24.0 ng/mL PSA 7.7-24.0 ng/mL PSA <7.7 ng/mL 0.8 0.6 0.4 0.2 0 1.0
    8. 8. Rising PSA in Non-Metastatic CRPC: PSA Doubling Time (PSADT) Smith MR, et al. J Clin Oncol 2005;23:2918-2925 . 0.5 1 1.5 2.0 2.5 3.0 Years since random assignment PSADT <6.3 months PSADT 6.3-18.8 months PSADT >18.8 months 0.8 0.6 0.4 0.2 0 1.0 Proportion of patients with bone metastases or death
    9. 9. # Bone Lesions and Risk for SRE > 3 Bone Lesions Versus ≤ 3 Bone Lesions Shirina N, et al. Presented at ASCO 2006. Poster 8529. In favor of less lesions In favor of more lesions Lung cancer and other solid tumors 1.54 Hazard ratio 0 0.5 1 1.5 2 1.41 1.51 Prostate cancer Breast cancer
    10. 10. <ul><li>3 Bone Lesions Associated With Shorter Time to SRE </li></ul>Baseline (n = 376) P < .0001 < 3 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0 3 6 9 12 15 18 21 24 Time since randomization, months Proportion with SRE > 3
    11. 11. <ul><li>3 Bone Lesions Associated With Shorter Survival </li></ul>Baseline (n = 376) P < .0001 0 3 6 9 12 15 18 21 24 Time since randomization, months Proportion died 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 < 3 > 3
    12. 12. Bone Markers
    13. 13. Prognostic Implications of Bone Markers: Relative Risks in Prostate Cancer P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.003 <0.001 0.001 3.82 3.03 All SRE First SRE NTX ≥100 nmol/mmol creatinine BAP ≥146 IU/L NTX 50–100 nmol/mmol creatinine Brown J et al. J Natl Cancer Inst . 2005;97:59. Death 4.31 2.65 3.25 3.05 4.59 3.10 3.19 0.1 1 10 Relative Risk (vs lowest marker category) NTX, N-telopeptide of type I collagen; BAP, bone-specific alkaline phosphatase
    14. 14. Normalization of NTX Levels vs Clinical Outcomes Among Patients With High NTX at Baseline 0 0.5 1.0 1.5 2.0 First SRE 0.61 38% .0411 Death 0.41 59% < .0001 In favor of normalized NTX In favor of persistently elevated NTX Saad et al. Sem Urol Oncol 2010 Lipton et al. Cancer 2009 Risk reduction P value
    15. 15. NTX Normalization Correlated With Improved Survival Versus Persistently Elevated NTX Proportion deceased, % patients Time on study, months (starting at month 3) 100 80 60 40 20 0 3 9 12 15 18 21 24 27 6 RR = 0.410 P < .001 E  E E  N
    16. 16. Survival Benefit by Percentage Reduction From Baseline NTX High NTX, NTX >64 nmol/mmol creatinine Relative Risk of Death 0 0.25 0.50 0.75 1.00 1.25 Median baseline NTX (125 nmol/mmol creatinine) 5 15 25 Patients with NTX decrease ≤ corresponding x-axis value 35 45 65 85 95 – 3 17 37 57 77 97 NTX Decrease From Baseline* (%) (Decrease vs Baseline) No change NTX correlated with risk of death *Calculated as ([Baseline NTX minus 3-month NTX] / baseline NTX) × 100.  
    17. 17. Survival by Percentage Change From Baseline NTX in Placebo Group *Calculated as ([Baseline NTX minus 3-month NTX] / baseline NTX) × 100. All patients in this analysis had baseline NTX > 64 nmol/mmol creatinine. Relative Risk of Death 95 85 65 45 35 25 15 5 3.00 2.75 2.50 2.25 2.00 1.75 1.50 1.25 1.00 0.75 0.50 0.25 0.00 -222 -202 -182 -162 -142 -122 -102 -82 -62 -42 -22 -2 18 38 58 78 98 Median baseline NTX (145 nmol/mmol creatinine NTX Decrease From Baseline* (%) (Increase vs Baseline) (Decrease vs BL) No change NTX  correlated with  risk of death Saad F et al . Presented at: AUA Annual Meeting; May 2008; Orlando, FL. Abstract 519.
    18. 18. Treatment options

    ×